Expression of cancer cell-intrinsic PD-1 associates with PD-L1 and p-S6 and predicts a good prognosis in nasopharyngeal carcinoma

Aims: Programmed cell death ligand 1 (PD-L1) is the ligand of programmed death 1 (PD-1), which is a host immunity inhibitory receptor. Expression of PD-L1 in diverse tumor types has been widely discussed, while there is little research about tumor intrinsic-PD-1. Phospho-S6 (p-S6) is an important downstream effector in the PI3K/AKT/mTOR pathway. Our study was focused on investigating expression of cancer cell-intrinsic PD-1, PD-L1 and p-S6 proteins and aimed to illustrate their relationship and clinical significances in nasopharyngeal carcinoma (NPC). Methods: The expression of PD-1, PD-L1 and p-S6 proteins in tissues of NPC, non-cancerous nasopharyngeal epithelia, primary cancer and matching metastatic lesion was detected by immunohistochemistry. Results: Expression of PD-1, PD-L1 and p-S6 proteins and co-expression of PD-1 and PD-L1 were significantly higher in NPC (all P<0.05). The expression of PD-1 and co-expression of PD-1 and PD-L1 in paired metastatic NPC were significantly increased (all P<0.01). NPC patients with positive expression of PD-L1 showed significantly higher overall survival rate (P =0.035). However, NPC patients with positive expression PD-1 and p-S6 showed significantly lower overall survival rate (P =0.031, P=0.044, respectively). Interestingly, NPC patients with co-expression of PD-1 and PD-L1 had lower overall survival rate (P=0.042). Multivariate Cox proportional hazard regression analysis confirmed that positive expression of PD-L1 and p-S6 were independent prognostic factors for NPC patients. Conclusions: Expression of cancer cell-intrinsic PD-1 associates with PD-L1 and p-S6 proteins, PD-L1 might serve as a good prognostic biomarker, while p-S6 could be an independent poor prognostic biomarker for NPC patients.

[1]  Wenchuan Wu,et al.  Cell-intrinsic PD-1 Promotes Proliferation in Pancreatic Cancer by Targeting CYR61/CTGF via the Hippo Pathway. , 2019, Cancer letters.

[2]  Xiao-Fang Yu,et al.  PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma , 2019, BMC Cancer.

[3]  Zhuchu Chen,et al.  Deciphering nasopharyngeal carcinoma pathogenesis via proteomics , 2019, Expert review of proteomics.

[4]  Zhihua Liu,et al.  The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy , 2019, Nature Communications.

[5]  M. Stoler,et al.  PD‐L1 and IDO expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy , 2018, Histopathology.

[6]  H. Baba,et al.  PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer , 2017, Annals of surgery.

[7]  N. Tsang,et al.  Low PD-L1 Expression Strongly Correlates with Local Recurrence in Epstein-Barr Virus-Positive Nasopharyngeal Carcinoma after Radiation-Based Therapy , 2018, Cancers.

[8]  Ludmila V. Danilova,et al.  Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab , 2018, Journal of Immunotherapy for Cancer.

[9]  H. Yao,et al.  Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy , 2018, Front. Immunol..

[10]  H. Yao,et al.  Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion , 2018, Front. Pharmacol..

[11]  Yi Fang,et al.  Tumor-Repopulating Cells Induce PD-1 Expression in CD8+ T Cells by Transferring Kynurenine and AhR Activation. , 2018, Cancer cell.

[12]  A. Dicker,et al.  Blockade of Tumor-Expressed PD-1 promotes lung cancer growth , 2017, Oncoimmunology.

[13]  Xinping Zhang,et al.  Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  B. Zhang,et al.  Programmed cell death‐1 (PD‐1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell–intrinsic PD‐1 , 2017, Hepatology.

[15]  C. Cao,et al.  Cytomembranic PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma , 2017, OncoTargets and therapy.

[16]  P. Lequerica-Fernández,et al.  Phosphorylated ribosomal protein S6 correlation with p21 expression and inverse association with tumor size in oral squamous cell carcinoma , 2017, Head & neck.

[17]  B. O'Sullivan,et al.  Overview of the 8th Edition TNM Classification for Head and Neck Cancer , 2017, Current Treatment Options in Oncology.

[18]  Min Li,et al.  Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes , 2017, Oncoimmunology.

[19]  Z. Zeng,et al.  Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma , 2017, Oncotarget.

[20]  J. Miao,et al.  PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load , 2017, Scientific Reports.

[21]  G. Tse,et al.  PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients , 2017, Breast Cancer Research and Treatment.

[22]  F. Izzo,et al.  CXCR4–CXCL12–CXCR7, TLR2–TLR4, and PD-1/PD-L1 in colorectal cancer liver metastases from neoadjuvant-treated patients , 2016, Oncoimmunology.

[23]  R. Weber,et al.  Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity‐modulated radiotherapy , 2016, Cancer.

[24]  Jinming Yu,et al.  PD-L1 expression in human cancers and its association with clinical outcomes , 2016, OncoTargets and therapy.

[25]  Zhaoxia Liu,et al.  Overexpression of Notch3 and pS6 Is Associated with Poor Prognosis in Human Ovarian Epithelial Cancer , 2016, Mediators of inflammation.

[26]  V. Lee,et al.  Correlation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma , 2016, PloS one.

[27]  H. Kalthoff,et al.  PD-L1 is an independent prognostic predictor in gastric cancer of Western patients , 2016, Oncotarget.

[28]  C. Jiang,et al.  Regulation of PD-L1: a novel role of pro-survival signalling in cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  George F. Murphy,et al.  Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth , 2015, Cell.

[30]  L. Bai,et al.  Survival and Prognostic Analysis of Primary Nasopharyngeal Carcinoma in North China. , 2015, Clinical laboratory.

[31]  S. Fan,et al.  Activation of Akt/mTOR Pathway Is Associated with Poor Prognosis of Nasopharyngeal Carcinoma , 2014, PloS one.

[32]  Rensheng Wang,et al.  Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: treatment outcomes of a prospective, multicentric clinical study. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[33]  Ji-xian Wang,et al.  mTOR activation in immature cells of primary nasopharyngeal carcinoma and anti-tumor effect of rapamycin in vitro and in vivo. , 2013, Cancer Letters.

[34]  Jason B. Williams,et al.  Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells , 2013, Science Translational Medicine.

[35]  I. Tham,et al.  Late toxicities after conventional radiation therapy alone for nasopharyngeal carcinoma. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[36]  C. Drake,et al.  Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. , 2012, Current opinion in immunology.

[37]  Alison P. Klein,et al.  Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.

[38]  I. Su,et al.  Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma , 2010, Modern Pathology.

[39]  W. Wen,et al.  Overproduction of cyclin D1 is dependent on activated mTORC1 signal in nasopharyngeal carcinoma: implication for therapy. , 2009, Cancer letters.

[40]  W. Cho,et al.  Nasopharyngeal carcinoma: molecular biomarker discovery and progress , 2007, Molecular Cancer.

[41]  M. Azuma,et al.  Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer , 2005, Clinical Cancer Research.

[42]  T. Honjo,et al.  Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. , 1992, The EMBO journal.

[43]  G. Crabtree,et al.  Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases , 1992, Cell.

[44]  Pelayo Vilar,et al.  Nasopharyngeal Carcinoma , 1966 .